Mefenamic acid
Mefenamic Acid, Ponstel (mefenamic acid) is a small molecule pharmaceutical. Mefenamic acid was first approved as Ponstel on 1982-01-01. It is used to treat dysmenorrhea, fever, menorrhagia, and premenstrual syndrome in the USA. The pharmaceutical is active against prostaglandin G/H synthase 2 and prostaglandin G/H synthase 1. In addition, it is known to target transient receptor potential cation channel subfamily M member 3 and potassium voltage-gated channel subfamily KQT member 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Mefenamic acid, Ponstel (discontinued: Mefenamic acid)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mefenamic acid
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PONSTEL | Avion Pharmaceuticals | N-015034 RX | 1982-01-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mefenamic acid | ANDA | 2024-08-15 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dysmenorrhea | D004412 | HP_0100607 | N94.6 | — | 2 | 1 | 1 | 1 | 4 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 1 | 1 | 1 | 3 |
| Uterine hemorrhage | D014592 | — | — | — | — | — | 1 | 1 | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | 2 | 1 | — | — | 2 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | 1 | — | 1 | 2 |
| Endometriosis | D004715 | EFO_0001065 | N80 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | — | G89.18 | — | 1 | — | — | — | 1 |
| Pulpitis | D011671 | EFO_1001139 | K04.0 | — | 1 | — | — | — | 1 |
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
| Metabolic side effects of drugs and substances | D065606 | — | — | 1 | — | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amenorrhea | D000568 | — | N91.2 | — | — | — | — | 1 | 1 |
| Infertility | D007246 | HP_0000789 | — | — | — | — | — | 1 | 1 |
| Impacted tooth | D014095 | HP_0011079 | K01.1 | — | — | — | — | 1 | 1 |
| Tooth diseases | D014076 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mefenamic acid |
| INN | mefenamic acid |
| Description | Mefenamic acid is an aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis. It has a role as an analgesic, an antirheumatic drug, a non-steroidal anti-inflammatory drug, an antipyretic, an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, an environmental contaminant and a xenobiotic. It is an aminobenzoic acid and a secondary amino compound. |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (anthranilic acid derivatives) and their salts or esters |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cccc(Nc2ccccc2C(=O)O)c1C |
Identifiers
| PDB | — |
| CAS-ID | 61-68-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL686 |
| ChEBI ID | 6717 |
| PubChem CID | 4044 |
| DrugBank | DB00784 |
| UNII ID | 367589PJ2C (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
AKR1C3
AKR1C3
Organism
Homo sapiens
Gene name
AKR1C3
Gene synonyms
DDH1, HSD17B5, KIAA0119, PGFS
NCBI Gene ID
Protein name
aldo-keto reductase family 1 member C3
Protein synonyms
17-beta-HSD 5, 17-beta-hydroxysteroid dehydrogenase type 5, 3-alpha hydroxysteroid dehydrogenase, type II, 3-alpha-HSD type 2, 3-alpha-HSD type II, brain, 3-alpha-hydroxysteroid dehydrogenase type 2, Chlordecone reductase homolog HAKRb, DD-3, DD3, Dihydrodiol dehydrogenase 3, Dihydrodiol dehydrogenase type I, dihydrodiol dehydrogenase X, HA1753, indanol dehydrogenase, PGFS, Prostaglandin F synthase, Testosterone 17-beta-dehydrogenase 5, trans-1,2-dihydrobenzene-1,2-diol dehydrogenase, type IIb 3-alpha hydroxysteroid dehydrogenase
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Mefenamic acid
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,969 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mefenamic acid
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,211 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use